Sangamo maintained by JMP at market outperform

Sangamo BioSciences Inc. was maintained at a market outperform rating by JMP Securities analyst Erin Seidemann with a price target on the stock of $8 per share. JMP said experts in diabetic neuropathy recently expressed enthusiasm for Sangamo's ZFP VEGF-A activator, which is rapidly moving through a phase I trial and could become the first disease modifying drug for treating diabetic neuropathy. Sangamo shares Monday were up $0.04, or 0.91%, at $4.43 on volume of 90,262 shares versus the three-month running average of 47,604.6 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.